Browse by People

Lefebvre, Carol, Glanville, Julie, Beale, Sophie ORCID: 0000-0003-0164-103X, Boachie, Charles, Duffy, Steven, Fraser, Cynthia, Harbour, Jenny, McCool, Rachael and Smith, Lynne (2017) Assessing the performance of methodological search filters to improve the efficiency of evidence information retrieval: five literature reviews and a qualitative study. HEALTH TECHNOLOGY ASSESSMENT, 21 (69). 1-+.

Stainthorpe, Angela, Fleeman, Nigel ORCID: 0000-0002-4637-9779, Houten, Rachel ORCID: 0000-0002-4315-7732, Chaplin, Marty, Boland, Angela ORCID: 0000-0002-5435-8644, Beale, Sophie ORCID: 0000-0003-0164-103X, Dundar, Yenal, McEntee, Joanne and Syndikus, Isabel (2020) Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 4 (4). pp. 563-574.

Fleeman, Nigel ORCID: 0000-0002-4637-9779, Stainthorpe, Angela, Houten, Rachel ORCID: 0000-0002-4315-7732, Chaplin, Marty ORCID: 0000-0002-7097-8704, Boland, Angela ORCID: 0000-0002-5435-8644, Beale, Sophie, Dundar, Yenal, Kotas, Eleanor, McEntee, Joanne and Isabel, Syndikus (2018) Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12). [Report]

Lambe, Tosin ORCID: 0000-0002-6229-2454, Duarte, Rui, Mahon, James, Nevitt, Sarah ORCID: 0000-0001-9988-2709, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Boland, Angela ORCID: 0000-0002-5435-8644, Beale, Sophie ORCID: 0000-0003-0164-103X, Kotas, Eleanor, McEntee, Joanne and Pomeroy, Ian (2019) Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 37 (3). pp. 345-357.

Duarte, Rui, Mahon, James, Nevitt, Sarah ORCID: 0000-0001-9988-2709, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Boland, Angela ORCID: 0000-0002-5435-8644, Beale, Sophie, Kotas, Eleanor and Mcentee, Joanne (2017) Cladribine for the treatment of relapsing-remitting multiple sclerosis. [Report]

Fleeman, Nigel ORCID: 0000-0002-4637-9779, Bagust, Adrian ORCID: 0000-0002-2142-5767, Beale, Sophie ORCID: 0000-0003-0164-103X, Boland, Angela ORCID: 0000-0002-5435-8644, Dickson, Rumona ORCID: 0000-0003-1416-0913, Dwan, Kerry, Richardson, Marty ORCID: 0000-0002-7097-8704, Dundar, Yenal, Davis, Helen and Banks, Lindsay (2015) Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. PHARMACOECONOMICS, 33 (9). pp. 893-904.

Houten, Rachel ORCID: 0000-0002-4315-7732, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Mahon, James, Nevitt, Sarah ORCID: 0000-0001-9988-2709, Beale, Sophie ORCID: 0000-0003-0164-103X, Boland, Angela ORCID: 0000-0002-5435-8644, Lambe, Tosin ORCID: 0000-0002-6229-2454, Dundar, Yenal, Kotas, Eleanor and McEntee, Joanne (2021) Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 5 (1). pp. 13-22.

Collapse authors list.
Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Bagust, Adrian ORCID: 0000-0002-2142-5767, Boland, Angela ORCID: 0000-0002-5435-8644, Dwan, Kerry, Beale, Sophie ORCID: 0000-0003-0164-103X, Hockenhull, Juliet ORCID: 0000-0002-2026-3778, Proudlove, Christine, Dundar, Yenal, Richardson, Marty ORCID: 0000-0002-7097-8704, Dickson, Rumona ORCID: 0000-0003-1416-0913 et al (show 2 more authors) , Mullard, Anna and Marshall, Ernie (2015) Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 19 (47). I-133.

Beale, Sophie ORCID: 0000-0003-0164-103X (2021) Keeping horses barefoot: a shared accomplishment. PhD thesis, University of Liverpool.

Collapse authors list.
Fleeman, Nigel ORCID: 0000-0002-4637-9779, Houten, Rachel ORCID: 0000-0002-4315-7732, Bagust, Adrian ORCID: 0000-0002-2142-5767, Richardson, Marty ORCID: 0000-0002-7097-8704, Beale, Sophie ORCID: 0000-0003-0164-103X, Boland, Angela ORCID: 0000-0002-5435-8644, Dundar, Yenal, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Hounsome, Juliet ORCID: 0000-0002-2026-3778, Duarte, Rui et al (show 1 more authors) and Shenoy, Aditya (2020) Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24 (2). 1-+.

Fleeman, Nigel ORCID: 0000-0002-4637-9779, Bagust, Adrian ORCID: 0000-0002-2142-5767, Boland, Angela ORCID: 0000-0002-5435-8644, Dwan, Kerry, Chaplin, Marty ORCID: 0000-0002-7097-8704, Beale, Sophie, Kotas, Eleanor, Banks, Lindsay and Greystoke, Alastair (2014) Nintedanib for previously treated locally advanced or metastatic non small cell lung cancer. [Report]

Stainthorpe, Angela ORCID: 0000-0002-2531-9371, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Bagust, Adrian ORCID: 0000-0002-2142-5767, Richardson, Marty ORCID: 0000-0002-7097-8704, Boland, Angela ORCID: 0000-0002-5435-8644, Beale, Sophie ORCID: 0000-0003-0164-103X, Duarte, Rui, Kotas, Eleanor, Banks, Lindsay and Palmer, Daniel ORCID: 0000-0002-7147-5703 (2018) Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36 (10). pp. 1153-1163.

Collapse authors list.
Bresnahan, Rebecca, Houten, Rachel ORCID: 0000-0002-4315-7732, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Nevitt, Sarah, Mahon, James, Beale, Sophie ORCID: 0000-0003-0164-103X, Boland, Angela ORCID: 0000-0002-5435-8644, Bhattacharyya, Devarshi, Dundar, Yenal, McEntee, Joanne et al (show 3 more authors) , Gandhi, Shreyans, Fleeman, Nigel ORCID: 0000-0002-4637-9779 and Chaplin, Marty (2023) Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open.

Fleeman, Nigel ORCID: 0000-0002-4637-9779, Abdulla, Ahmed, Bagust, Adrian ORCID: 0000-0002-2142-5767, Beale, Sophie ORCID: 0000-0003-0164-103X, Richardson, Marty ORCID: 0000-0002-7097-8704, Stainthorpe, Angela ORCID: 0000-0002-2531-9371, Boland, Angela ORCID: 0000-0002-5435-8644, Kotas, Eleanor, McEntee, Joanne and Palmer, Daniel ORCID: 0000-0002-7147-5703 (2018) Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 36 (3). pp. 289-299.

Fleeman, Nigel ORCID: 0000-0002-4637-9779, Bagust, Adrian ORCID: 0000-0002-2142-5767, Beale, Sophie ORCID: 0000-0003-0164-103X, Dwan, Kerry, Dickson, Rumona ORCID: 0000-0003-1416-0913, Proudlove, Chris and Dundar, Yenal (2015) Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. PHARMACOECONOMICS, 33 (1). pp. 13-23.

Hounsome, Juliet ORCID: 0000-0002-2026-3778, Pilkington, Gerlinde ORCID: 0000-0003-0028-0746, Mahon, James, Boland, Angela ORCID: 0000-0002-5435-8644, Beale, Sophie ORCID: 0000-0003-0164-103X, Kotas, Eleanor, Renton, Tara and Dickson, Rumona ORCID: 0000-0003-1416-0913 (2020) Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation. Health Technology Assessment, 24 (30). 1-+.

Collapse authors list.
Fleeman, Nigel ORCID: 0000-0002-4637-9779, Bagust, Adrian ORCID: 0000-0002-2142-5767, Boland, Angela ORCID: 0000-0002-5435-8644, Beale, Sophie ORCID: 0000-0003-0164-103X, Richardson, Marty ORCID: 0000-0002-7097-8704, Krishan, Ashma, Stainthorpe, Angela ORCID: 0000-0002-2531-9371, Abdulla, Ahmed, Kotas, Eleanor, Banks, Lindsay et al (show 1 more authors) and Payne, Miranda (2017) Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 35 (10). pp. 1035-1046.

Collapse authors list.
Fleeman, Nigel ORCID: 0000-0002-4637-9779, Bagust, Adrian ORCID: 0000-0002-2142-5767, Boland, Angela ORCID: 0000-0002-5435-8644, Beale, Sophie, Chaplin, Marty ORCID: 0000-0002-7097-8704, Krishan, Ashma, Stainthorpe, Angela, Abdulla, Ahmed, Kotas, Eleanor, Banks, Lindsay et al (show 1 more authors) and Payne, Miranda (2016) Talimogene laherparepvec for treating metastatic melanoma. [Report]

Nicholson, Amanda, Mahon, James, Boland, Angela ORCID: 0000-0002-5435-8644, Beale, Sophie ORCID: 0000-0003-0164-103X, Dwan, Kerry, Fleeman, Nigel ORCID: 0000-0002-4637-9779, Hockenhull, Juliet ORCID: 0000-0002-2026-3778 and Dundar, Yenal (2015) The clinical effectiveness and cost-effectiveness of the PROGENSA (R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technology Assessment, 19 (87). 1-+.

Collapse authors list.
Mahon, James, Beale, Sophie ORCID: 0000-0003-0164-103X, Holmes, Hayden ORCID: 0000-0003-2559-061X, Arber, Mick, Nikolayevskyy, Vladyslav, Alagna, Riccardo, Manissero, Davide ORCID: 0000-0002-8887-8795, Dowdy, David, Migliori, Giovanni Battista, Sotgiu, Giovanni et al (show 1 more authors) and Duarte, Raquel (2022) A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations. BMC pulmonary medicine, 22 (1). 375-.

Fleeman, Nigel ORCID: 0000-0002-4637-9779, Houten, Rachel ORCID: 0000-0002-4315-7732, Chaplin, Marty ORCID: 0000-0002-7097-8704, Beale, Sophie ORCID: 0000-0003-0164-103X, Boland, Angela ORCID: 0000-0002-5435-8644, Dundar, Yenal, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Duarte, Rui and Shenoy, Aditya (2019) A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC CANCER, 19 (1). 1209-.